

Artificial Intelligence Across Radiology, Laboratory Medicine, Optometry, Dentistry, and Nursing: A Scoping Review of Clinical Applications, Workforce Readiness, and Patient Safety

¹Yousef Ghalib Saleh Alhashim, ²Jehad Hassan Jawad Albashrawi, ³Alanood Nasser Abdullah Bin Jawhar, ⁴Malak Fahad Aldossary, ⁵Masbobah Salem Mubarak aldossary, ⁶Ashwag Hamad Aldossari, ⁷Khalid Saad Said Ghayeb, ⁸Asma Naif R. Almutairi, ⁹Hussain Ayedh Awadh Alqahtani, ¹⁰Hajer Ibrahim Ali Alorainy, ¹¹Saeed Abdullah Al Bagedy, ¹²Khalid Alaiwi S. Alanazi,

¹Medical Laboratory Technologist, Security Forces Hospital, Dammam, Saudi Arabia.

² X-ray Technician, Security Forces Hospital, Dammam, Saudi Arabia.

³ Optometry Doctor, Al-Nakheel Medical Center, Ministry of Defense, Riyadh, Saudi Arabia.

⁴Dental Assistant, Prince Abdulrahman Advanced Dental Institute, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.

⁵Dental Assistant, Prince Abdulrahman Advanced Dental Institute, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.

⁶Assistant Dentist, Prince Abdulrahman Advanced Dental Institute, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.

⁷Optometry Doctor, General Department of Medical Services, Presidency of State Security; King Saud University, Riyadh, Saudi Arabia.

⁸Optometry Doctor, General Department of Medical Services, Presidency of State Security; King Saud University, Riyadh, Saudi Arabia.

⁹Optometry Specialist, General Department of Medical Services, Presidency of State Security; King Saud University, Riyadh, Saudi Arabia.

¹⁰Medical Laboratory Technician, King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia.

¹¹Nurse, Emergency Department, Security Forces Hospital, Riyadh, Saudi Arabia.

¹²Nurse, Emergency Department, Security Forces Hospital, Riyadh, Saudi Arabia.

HOW TO CITE:

Yousef Ghalib Saleh Alhashim, Jehad Hassan Jawad Albashrawi, Alanood Nasser Abdullah Bin Jawhar, Malak Fahad Aldossary, Masbobah Salem Mubarak aldossary, Ashwag Hamad Aldossari, Khalid Saad Said Ghayeb, Asma Naif R. Almutairi, Hussain Ayedh Awadh Alqahtani, Hajer Ibrahim Ali Alorainy, Saeed Abdullah Al Bagedy, Khalid Alaiwi S. Alanazi, (2026). Artificial Intelligence Across Radiology, Laboratory Medicine, Optometry, Dentistry, and Nursing: A Scoping Review of Clinical Applications, Workforce Readiness, and Patient Safety. International Journal of Special Education, 41(19s),637 - 652

ABSTRACT:

This scoping review maps the integration of artificial intelligence (AI) across radiology, laboratory medicine, optometry, dentistry, and nursing, assessing clinical applications, workforce readiness, and patient safety. Following PRISMA-ScR guidelines, it evaluates workflow optimizations and generalization challenges, such as the domain shift phenomenon in radiology. The review highlights the realization of autonomous diagnostics in optometry and the use of high-specificity adjunctive screening in dentistry. It contrasts the predictive failures of proprietary sepsis models with open-source successes and explores the generation of synthetic data in pathology. Furthermore, it addresses the nursing deskilling paradox, critiques the fundamental flaws of

COPYRIGHT STATEMENT:
 Copyright: © 2026 Authors.
 Open access publication under the
 terms and conditions
 of the Creative Commons Attribution (CC BY)
 license (<http://creativecommons.org/licenses/by/4.0/>).

post-hoc explainable AI, and examines the Saudi Food and Drug Authority regulatory framework under the Vision 2030 initiative.

Keywords: Artificial Intelligence; Clinical Decision Support; Patient Safety; Explainable AI; Saudi Vision 2030

Introduction and Methodological Framework

The integration of artificial intelligence (AI), machine learning (ML), and deep learning (DL) into contemporary healthcare systems represents a fundamental paradigm shift that extends far beyond the mere digitization of medical records. This technological evolution fundamentally alters clinical workflows, diagnostic paradigms, the ontology of disease classification, and the underlying nature of the provider-patient relationship. As computational architectures advance from isolated image classifiers to integrated, multimodal clinical decision support systems, the medical community faces unprecedented opportunities for workflow optimization alongside novel vulnerabilities related to algorithmic bias, clinical deskilling, and regulatory ambiguity. This scoping review maps the breadth and depth of AI applications across five distinct but operationally interconnected clinical domains: radiology, laboratory medicine, optometry, dentistry, and nursing. Furthermore, the analysis critically assesses workforce readiness, algorithmic transparency, and patient safety, particularly within the context of the Saudi Vision 2030 digital health transformation.

To systematically navigate this highly complex and heterogeneous landscape, this analysis is grounded in the structural philosophy of the PRISMA-ScR (Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews) guidelines, published by Tricco et al. in 2018 and endorsed by the EQUATOR Network [1]. The core PRISMA 2020 checklist was designed explicitly for systematic reviews that evaluate the efficacy of focused clinical interventions, typically structured around the PICO (Population, Intervention, Comparison, Outcome) framework, and often

culminating in a meta-analysis weighted by risk of bias. Conversely, a scoping review serves a fundamentally different epistemological purpose: it is engineered to map the extent, range, and nature of evidence on a broader topic, clarify key concepts, and identify critical gaps in the literature without necessarily pooling effect estimates [1].

Consequently, the PRISMA-ScR requires framing research questions within the PCC (Population, Concept, Context) framework. For the purposes of this extensive review, the Population comprises the diverse spectrum of healthcare professionals—radiologists, medical laboratory technologists, optometrists, dentists, and nurses—alongside the patients interacting with AI-augmented care systems. The Concept encompasses the clinical deployment of AI technologies, the psychological and educational readiness of the workforce to adopt these tools, and the structural imperatives of patient safety and explainable AI (XAI). The Context focuses on global clinical environments, with a highly specific translational focus on the regulatory, educational, and systemic landscape of the Kingdom of Saudi Arabia, heavily influenced by the Saudi Commission for Health Specialties (SCFHS) and the Saudi Food and Drug Authority (SFDA) [2].

The PRISMA-ScR methodology mandates a 22-item checklist (20 essential and 2 optional items) that ensures complete methodological transparency in how evidence is charted and mapped. Unlike standard systematic reviews, quality assessment of included studies under PRISMA-ScR is considered optional, allowing researchers to cast a wider net over heterogeneous disciplines and study designs, which is strictly necessary when evaluating a phenomenon as ubiquitous and rapidly evolving

as medical artificial intelligence [3].

Artificial Intelligence in Radiology: The Generalization Crisis and Workflow Optimization

Radiology has historically served as the vanguard of medical AI, a position facilitated by the early digitization of imaging via PACS (Picture Archiving and Communication Systems) and the abundance of standardized, structured data required to train convolutional neural networks (CNNs) [4]. The transition of AI from experimental computer vision tasks to clinically validated, FDA-cleared medical devices has been particularly pronounced in this domain [5].

Diagnostic Maturation Versus Interventional Latency

The deployment of AI across radiological workflows demonstrates a stark dichotomy between diagnostic imaging and interventional procedures. In diagnostic workflows, such as MRI and CT screening, AI algorithms achieve remarkable internal validation metrics, demonstrating up to 94% segmentation accuracy and 95% nodule detection sensitivity [6]. An analysis of the radiological literature reveals that the most common primary tasks undertaken by AI models are segmentation (39%), followed by classification (31%) and identification [7]. Currently, sophisticated AI solutions are commercially available to support 70% of standard MRI workflow steps and 64% of CT workflow steps. These tools fundamentally optimize image acquisition and reconstruction, achieving scan time reductions ranging from 30% to 75%, and accelerating diagnostic reporting by 30% to 50% through the automated

prioritization of critical findings [6]. The integration of radiomics and predictive modeling further facilitates the noninvasive phenotyping of tissue characteristics, moving radiology beyond morphological description into the realm of molecular surrogate forecasting [4].

Conversely, interventional radiology workflows, such as coronary stenting and liver cryoablation, exhibit significantly lower AI maturity [6]. Currently, only 55% of steps in coronary stenting and 36% in liver cryoablation possess available AI support. While emerging interventional applications improve catheter navigation, probe placement, and ablation success, they still necessitate profound human oversight. The latency in interventional AI is primarily due to the immense computational complexity of real-time spatial optimization, the unpredictable nature of intraoperative tissue deformation, and the higher clinical risks associated with automated physical interventions compared to passive image interpretation [6].

The Domain Shift Phenomenon and External Validation

Despite the exceptional performance of CNNs on internal institutional datasets, the radiological AI landscape is plagued by the "generalization problem." A comprehensive systematic review evaluating 86 deep-learning algorithms in radiology revealed a disturbing trend: 81% of models exhibited a measurable decrease in accuracy when applied to external datasets, with nearly a quarter experiencing a substantial performance collapse defined as a drop of at least 0.10 in the Area Under the Curve (AUC) [5].




Figure 1: Diagnostic AI Generalization and Domain Shift.

When AI models are deployed across different centers, they inevitably encounter "domain shifts"—variations in scanner hardware, proprietary reconstruction algorithms, imaging protocols, disease prevalence, and underlying patient demographics. While diagnostic sensitivities often remain above 85% during external validation, specificities frequently suffer severe declines, dropping by up to 24 percentage points [5]. This phenomenon reveals a critical third-order insight: robust internal validation is mathematically necessary but clinically insufficient to guarantee safety. The vast majority of radiological AI studies (98%) are retrospective

in design, and a significant portion modify "off-the-shelf" models (such as U-Net or ResNet) without adequate fine-tuning for local population variance [7]. To mitigate domain shift, researchers are increasingly employing Generative Adversarial Networks (GANs) for synthetic data augmentation, which in some instances has increased a model's external AUC from 0.836 to 0.933. However, achieving true global optimality requires multicenter training regimens that deliberately minimize the model's dependence on highly localized, non-pathological demographic attributes [5].

Table 1. Applications, Architectures, and Generalizability Challenges of Artificial Intelligence in Radiology

Clinical Sub-domain	Predominant AI Architectures	Key Workflow Optimizations	Generalizability Challenges
Diagnostic MRI/CT	U-Net, ResNet, Custom CNNs	30-75% scan time reduction; 94% segmentation accuracy	Severe specificity degradation (up to 24%) across different scanner hardware and populations [5].
Interventional Radiology	Reinforcement Learning, Spatial Tracking	Catheter navigation, real-time probe placement	High latency; requires intense human oversight; poor real-time adaptability [6].
Predictive Radiomics	Multi-domain CNNs, Random Forests	Noninvasive tissue phenotyping, survival prediction	High susceptibility to demographic bias and overfitting on single-center retrospective data [4].

Predictive Analytics and The Sepsis Conundrum

Beyond image analysis, artificial intelligence is extensively deployed in predictive modeling, utilizing structured and unstructured electronic health record (EHR) data to forecast clinical deterioration. Sepsis, characterized by life-threatening organ dysfunction caused by a dysregulated host response to infection, represents one of the most critical targets for AI-driven early warning systems due to its high mortality rate and the time-sensitive nature of therapeutic intervention [8].

The Epic Sepsis Model (ESM): A Cautionary Tale

The widespread deployment of the Epic Sepsis

Model (ESM) serves as a profound historical lesson on the dangers of sample selection bias and the premature commercialization of predictive AI. The ESM, a proprietary penalized logistic regression model embedded within the Epic EHR system, was implemented across hundreds of hospitals in the United States to generate automated alerts warning clinicians of impending sepsis [9]. The developers originally reported robust performance metrics, boasting an AUC between 0.76 and 0.83 [10].

However, independent external validation of the ESM at a large academic medical center, analyzing 38,455 hospitalizations, revealed catastrophic performance degradation. In this real-world deployment, the ESM achieved an

AUC of only 0.63, a sensitivity of 33%, a specificity of 83%, and a positive predictive value (PPV) of merely 12% [9]. The model failed to detect 67% of actual sepsis cases while simultaneously generating alerts on 18% of all hospitalized patients [11].

The systemic implications of these metrics are severe. A PPV of 12% indicates an overwhelming false-positive rate, meaning clinicians were forced to evaluate 109 patients to detect a single case of sepsis earlier than they would have through standard clinical observation [10]. This dynamic creates intense "alert fatigue," a phenomenon where healthcare providers become desensitized to warnings, ultimately leading them to ignore alerts entirely, thereby degrading patient safety and wasting critical nursing and medical resources [12]. The ESM controversy highlights the "clinical utility boundary": validating a model's statistical performance is distinct from proving that its deployment actually improves patient outcomes in a randomized controlled trial.

Benchmarking Success: MIMIC-IV and eICU Predictive Models

In stark contrast to the failures of proprietary, locked algorithms like the ESM, the open-source data science community has leveraged massive critical care databases—such as the Medical Information Mart for Intensive Care IV (MIMIC-IV), the eICU Collaborative Research Database (eICU-CRD), and the AmsterdamUMCdb—to develop highly robust,

interpretable machine learning models for sepsis prediction [13].

Recent systematic evaluations of these datasets demonstrate that modern ensemble learning techniques significantly outperform traditional clinical scoring systems like SOFA and APACHE [14]. For example, studies utilizing the eXtreme Gradient Boosting (XGBoost) model on MIMIC-IV data achieved an AUC of 0.94 and an F1 score of 0.937 in predicting in-hospital mortality among septic patients [13]. Feature importance analysis, facilitated by SHapley Additive exPlanations (SHAP), revealed that variables such as patient age, aspartate aminotransferase (AST), blood urea nitrogen (BUN), N-terminal pro-B-type natriuretic peptide (NTproBNP), Glasgow Coma Scale (GCS) score, and the requirement for invasive mechanical ventilation were the most potent predictors of mortality and sepsis-induced cardiomyopathy (SICM) [15].

Furthermore, models like CATBoost have been specifically trained to predict sepsis risk in niche, highly vulnerable ICU populations, such as patients with non-traumatic subarachnoid hemorrhage, achieving AUCs of 0.887 and maintaining performance fluctuation between training and test sets of less than 2% [16]. This stability indicates that when ML algorithms are trained on highly granular, multi-parameter physiological data and subjected to rigorous internal and external validation, they can provide genuine, life-saving clinical decision support.




Figure 2: Efficacy of Sepsis Prediction Models.

Table 2. Comparative Performance and Clinical Vulnerabilities of Sepsis Prediction Models

Sepsis Prediction Model	Data Source / Clinical Context	Core ML Architecture	Validation Performance (AUC)	Key Clinical Vulnerabilities
Epic Sepsis Model (ESM)	Proprietary EHR / General Inpatient	Penalized Logistic Regression	0.63 (External Validation)	Sensitivity of 33%; PPV of 12%; induces severe alert fatigue [9].
MIMIC-IV Benchmark Models	MIMIC-IV, eICU-CRD / ICU Sepsis	XGBoost, Random Forest, GBDT	0.78 - 0.94 (External Validation)	Requires high-quality, continuous physiological data streams [15].
Sepsis ImmunoScore (Prenosis)	10 Hospitals / Rapid Diagnostic	Hybrid ML (22 parameters inc. PCT)	0.80 - 0.85 (FDA De Novo)	Reliance on specific biomarker availability (procalcitonin, CRP) [12].

Artificial Intelligence in Optometry: The Vanguard of Autonomous Diagnostics

Optometry and ophthalmology have rapidly assimilated artificial intelligence, driven by the geometric complexity of retinal imaging and the escalating global prevalence of vision-threatening metabolic diseases. The retina provides a direct, non-invasive observation window into the human microvascular and central nervous systems, making it an ideal substrate for deep learning applications [17].

Diabetic Retinopathy and Macular Degeneration

Diabetic retinopathy (DR) and diabetic macular edema (DME) constitute primary targets for optometric AI [17]. Traditional screening programs face insurmountable challenges related to the availability of human accessors, financial sustainability, and intra-observer grading variability [18]. The integration of Optical

Coherence Tomography (OCT) with CNNs provides a transformative solution, automating the detection and classification of subtle retinal morphologies [19].

State-of-the-art algorithms trained on fundus photographs and OCT volumes achieve extraordinary diagnostic performance, frequently reporting sensitivities up to 96% and specificities up to 98% for detecting referable DR [17]. Researchers utilizing advanced architectures, such as ResNet-based lesion-aware sub-networks and Generative Adversarial Networks (GANs), have successfully segmented minute DR lesions, including microaneurysms, hard exudates, and cotton-wool spots, achieving overall grading AUCs averaging 0.955 [20]. In hybrid AI-clinician workflows, deep learning systems have demonstrated expert-level reliability for 11 out of 13 specific retinal biomarkers across large patient cohorts. While CNNs excel at quantifying intraretinal and subretinal fluid (yielding strong

Dice coefficients between 0.61 and 0.67), they still struggle with the precise segmentation of highly complex, atypical presentations, such as sub-retinal pigment epithelium (sub-RPE) lesions [21].

Autonomous Screening and Tele-Retinal Networks

The most profound systemic impact of AI in optometry is the realization of true autonomous diagnostics. Unlike traditional clinical decision support (CDS) tools that provide a second opinion to a physician, autonomous AI devices render a definitive medical decision without requiring human interpretation [17].

The FDA's authorization of the IDx-DR system marked a historical inflection point; this device is explicitly indicated for use by primary healthcare providers to screen for more-than-mild DR, autonomously referring positive cases to specialists [18]. Following this, systems like EyeArt and smartphone-based AI devices, such as the Remidio Fundus On Phone (FOP NM-10), have received regulatory clearance, facilitating out-of-clinic, point-of-care diagnostics [18]. The healthcare infrastructure has adapted to this paradigm shift, evidenced by the establishment of the Current Procedural Terminology (CPT) code 92229 in 2021, which explicitly allows for billing and reimbursement for the use of autonomous AI technology in retinal diagnostics [22]. This regulatory and financial validation underscores a broader systemic strategy to democratize access to preventative care, particularly in resource-constrained environments.

Artificial Intelligence in Dentistry: Adjunctive Screening and Overdiagnosis Prevention

The application of artificial intelligence in dentistry, while slightly trailing the autonomous milestones achieved in optometry, demonstrates robust utility in the analysis of bitewing radiography, panoramic imaging, and Cone Beam Computed Tomography (CBCT) [23].

Caries Detection and Periodontal Assessment

CNN models designed for dental applications

have shown exceptional capabilities in automating the detection of dental caries, periapical lesions, and the highly complex morphology of alveolar bone loss [23]. In the specialized field of implantology, AI facilitates the rapid identification of dental implant types, supports guided implant surgeries, and monitors the progression of peri-implant bone loss and mechanical implant fractures [24]. Meta-analyses comparing AI performance to traditional clinical review indicate that AI possesses superior sensitivity and equivalent specificity for detecting dental caries on standard clinical images [25].

Mitigating the Risk of Overtreatment

A critical third-order insight regarding dental AI is its optimal positioning as a high-specificity screening adjunct rather than a definitive diagnostic authority. AI-based decision support tools in dentistry generally exhibit high specificity and a high Negative Predictive Value (NPV). This statistical profile is clinically highly advantageous: it allows dental practitioners to confidently trust negative algorithmic findings, thereby avoiding the misdiagnosis of artifacts as pathology, preventing unnecessary restorative interventions, and mitigating the ethical risks of overtreatment [26]. However, because AI performance can exhibit significant variability across different commercial platforms and diverse patient populations, clinicians must retain strict oversight and independently confirm any positive findings generated by the AI before initiating irreversible restorative or surgical procedures [25].

Artificial Intelligence in Laboratory Medicine: Digital Pathology and Synthetic Data

Laboratory medicine is undergoing a profound digital metamorphosis, transitioning from traditional microscopic analysis and standard biochemical assays toward a highly integrated ecosystem characterized by big data analytics and precision medicine [27].

The Digital Pathology Revolution

The cornerstone of this transformation is the advent of digital pathology systems, which

convert physical glass slides into high-resolution Whole Slide Images (WSI) [27]. This digitization is not merely a logistical convenience; it is the prerequisite for applying deep learning to histopathology. Convolutional networks can now segment and classify every leukocyte in a digital blood smear in a matter of seconds, achieving diagnostic concordance with expert hematopathologists while processing hundreds of slides per hour [28].

In oncology, AI facilitates the objective, auditable quantification of critical surrogate endpoints, such as Pathological Complete Response (pCR), which were previously subject to high inter-observer variability [29]. Furthermore, the emerging field of Spatial Biology utilizes AI to extract complex, high-dimensional topological metrics from the Tumor Microenvironment (TME), mapping the intricate physical relationships between immune infiltrates and malignant cells to predict response to immunotherapy [29]. Traditionally, laboratory oncology has heavily relied on the manual quantification of specific serum biomarkers and individual genetic variants to evaluate disease predisposition and clinical risk profiles [30]. However, modern AI and advanced proteomics now transcend these conventional single-biomarker paradigms by utilizing sparse ML models—analyzing up to 3,000 distinct plasma proteins simultaneously—to improve ten-year risk predictions for both rare and common diseases, vastly outperforming standard clinical scoring rubric [28].

Pre-analytical Vulnerabilities

Despite the immense analytical power of ML in the laboratory, these models are exceptionally vulnerable to the foundational tenets of quality control. Variations in pre-analytical factors—such as specimen collection techniques, transport conditions, storage temperatures, tube mixing protocols, and tube additives—can introduce profound, non-random bias into the training data [31]. If an AI model learns to associate a pre-analytical artifact (e.g., hemolysis patterns caused by a specific hospital's pneumatic tube system) with a clinical outcome, the model will fail

catastrophically when deployed at a different institution. Consequently, the College of American Pathologists (CAP) and other governing bodies emphasize that the validation of ML models in laboratory medicine must be subjected to rigorous external proficiency testing and standardized performance metrics, such as Brier scores for model calibration and decision curve analysis for net clinical benefit [31].

The Role of Generative AI and Synthetic Data

A significant barrier to the development of robust medical AI is the scarcity of high-quality data, heavily constrained by patient privacy regulations such as HIPAA and the GDPR. To overcome these limitations, laboratory medicine and radiology are increasingly relying on Generative Adversarial Networks (GANs) and Variational Autoencoders (VAEs) to produce synthetic medical data [32].

A GAN operates through the adversarial training of two neural networks: a generator that creates artificial data from random noise, and a discriminator that attempts to classify the data as real or fake. Through continuous feedback, the generator learns to produce synthetic datasets—such as tabular EHR data, complex MRI images, or high-dimensional genomic sequences—that perfectly replicate the statistical distributions and intricate variable relationships of the original patient cohort, yet contain absolutely no traceable Protected Health Information (PHI) [32].

Different GAN architectures serve specific clinical needs: Deep Convolutional GANs (DCGANs) generate high-resolution medical images; Conditional GANs (cGANs) create data conditioned on specific diseases, such as generating artificial records for patients with rare tumors; and TimeGANs simulate continuous physiological signals like ECGs. Advanced implementations, such as Differentially Private CGANs (DP-CGANs), inject statistical noise into the network's gradients during training to provide mathematical guarantees of privacy [33]. By utilizing synthetic data, institutions can safely share information globally, augment datasets for

underrepresented demographic groups or rare diseases, and conduct simulated clinical trials, significantly accelerating research without compromising patient confidentiality [32].

Artificial Intelligence in Nursing: Efficiency, Empathy, and the Deskillling Paradox

Nurses operate at the critical nexus of technology and direct patient care. As frontline caregivers, they consistently face heavy physical workloads, extreme cognitive demands, and high-stakes clinical responsibilities, leading to significant rates of occupational stress, burnout, and compassion fatigue [34]. The integration of AI into nursing practice holds immense promise for alleviating these burdens, provided it is implemented to augment, rather than replace, human judgment.

Workload Optimization and Administrative Automation

AI-assisted nursing care is defined by several core attributes: data-driven decision support, the automation of routine tasks, enhanced predictive capabilities, and the personalization of care. Clinical Decision Support Systems (CDSS) process massive volumes of EHR data, vital signs, and laboratory results to provide real-time, evidence-based recommendations, supporting nurses in patient triage, medication reconciliation, and personalized drug dosing [35].

The automation of administrative tasks offers the most immediate relief to nursing workloads. Natural Language Processing (NLP) systems are increasingly utilized to transcribe nurse-patient interactions, automatically generate clinical notes, and populate health records, significantly reducing the documentation burden and improving record accuracy [36]. Furthermore, AI-driven scheduling algorithms optimize workforce allocation by dynamically analyzing staff availability, patient acuity, and historical workload patterns, thereby reducing overtime costs and mitigating staff fatigue [37]. AI-powered chatbots and virtual nursing assistants also handle routine patient inquiries, freeing human nurses to focus on complex, high-acuity interventions [36].

The impact of these tools is empirically measurable. Metrics such as the MIDENF Scale quantify workload reduction by scoring the time and effort required for tasks pre- and post-automation, while Cumulative Sum (CUSUM) analysis tracks the ongoing adaptability and performance improvement of continuous monitoring systems [35].

The Ethical Dilemma: Empathy and Deskillling

Despite substantial operational efficiencies, AI in nursing introduces profound ethical and professional risks. According to Cognitive Load Theory (CLT), while reducing clinical workload can improve decision-making quality, an over-reliance on automated systems can paradoxically degrade clinical competence [34]. This phenomenon, known as the "deskilling paradox," occurs when nurses—particularly younger or less experienced practitioners—rely too heavily on AI-generated predictive scores (such as an AI-augmented Modified Early Warning Score [MEWS]) to identify patient deterioration [35]. When algorithms assume the burden of clinical reasoning, the uniquely human skills of intuitive observation, critical thinking, and the ability to detect subtle, non-quantifiable signs of distress can atrophy [38].

Furthermore, the integration of AI risks disrupting the fundamental nurse-patient relationship, which is anchored in human dignity, autonomy, and vulnerability [37]. While machine learning can analyze a patient's verbal and non-verbal expressions to detect early warning signals of violent tendencies or psychological distress, treating a patient purely as an algorithmic data point strips away the necessary context of human empathy. To preserve the integrity of the profession, AI must be strictly positioned as an assistive tool, utilized primarily to eliminate administrative friction so that nurses can redirect their time and cognitive resources back toward direct, compassionate patient interaction [37].

Workforce Readiness and the Educational Paradigm Shift

The successful, safe deployment of AI across these diverse clinical disciplines requires a

healthcare workforce that is digitally literate, critically analytical, and highly adaptable. However, a systemic gap persists between the rapid pace of technological innovation and the relatively static nature of medical and nursing education curricula.

The Saudi Arabian Context and Vision 2030

Within the Kingdom of Saudi Arabia, the digitalization of healthcare and the adoption of AI are strategic imperatives enshrined in the Vision 2030 initiative. The Saudi Data and Artificial Intelligence Authority (SDAIA) leads massive strategic investments to build digital infrastructure, integrating AI across hospitals, research institutions, and groundbreaking projects like the Seha Virtual Hospital [39].

However, translating national strategy into frontline workforce readiness remains a significant challenge. Postgraduate clinical training programs in Saudi Arabia are overseen by the Saudi Commission for Health Specialties (SCFHS), which utilizes the CanMEDS framework [40]. Currently, these training programs and university curricula generally lack structured, formal education on AI, machine learning, and digital health data governance. Surveys evaluating the Knowledge, Attitude, and Practice (KAP) of EBP and AI among Saudi healthcare trainees reveal a workforce that is enthusiastic but underprepared [41]. For example, 79% of surveyed Saudi nursing students expressed strong support for integrating AI training into their curricula, recognizing positive correlations between AI usability and their own critical thinking motivation. Yet, a substantial majority report having little to no formal exposure to the underlying mechanics of the technology [42]. In gastroenterology and radiology, residents and clinicians similarly report limited exposure to AI concepts, leaving them under-prepared to critically evaluate, safely implement, or oversee the integration of these powerful tools into clinical practice [43].

Epistemic Trust and the Hidden Curriculum

The introduction of Generative AI (such as advanced large language models) into the educational environment creates a complex

"hidden curriculum." This hidden curriculum refers to the informal, implicit messages conveyed to learners through institutional culture, policies, and the observed behaviors of faculty. If clinical instructors quietly utilize AI tools for efficiency (e.g., drafting discharge summaries or synthesizing literature) while simultaneously penalizing students for similar use due to concerns over academic integrity, it fosters moral dissonance and confusion regarding professional responsibility [40].

Medical education must evolve beyond teaching basic computer literacy; it must cultivate advanced "epistemic trust." Clinicians must be trained to interrogate AI outputs critically, understand the statistical limitations of the models they use, and recognize the clinical manifestations of algorithmic drift and data bias. Educational frameworks must modernize the concept of Evidence-Based Practice (EBP) to include the critical appraisal of machine learning algorithms with the same rigor traditionally applied to randomized controlled trials [41].

Algorithmic Accountability and the Explainability Trap

As AI systems assume a greater role in high-stakes clinical decision-making, the inherent opacity of deep learning models—commonly referred to as the "black box" problem—emerges as a critical threat to patient safety and clinical trust. If a clinician cannot understand why an algorithm recommended a specific intervention, they cannot legally or ethically defend that decision.

The Failure of Post-Hoc XAI

To address this opacity, the field of Explainable Artificial Intelligence (XAI) has proliferated, developing post-hoc visualization tools designed to illuminate the inner workings of complex neural networks [44]. The most dominant techniques include Gradient-weighted Class Activation Mapping (Grad-CAM), Local Interpretable Model-agnostic Explanations (LIME), and SHapley Additive exPlanations (SHAP) [45]. Grad-CAM, for instance, calculates the gradient of the class score concerning each feature map in the final convolutional layer,

projecting a "heat map" over the original image to highlight the regions that most strongly influenced the model's prediction [44]. SHAP utilizes cooperative game theory to assign an importance value to each individual clinical feature [45].

Despite their widespread adoption, rigorous meta-analyses reveal that these post-hoc XAI techniques are fundamentally flawed and pose a hidden danger to clinical decision-making [46]. Quantitative assessments of XAI fidelity—the degree to which the explanation accurately reflects the model's actual mathematical reasoning—show alarming deficits. In medical imaging, while LIME achieves a relatively high

fidelity score of 0.81, Grad-CAM achieves only 0.54, and SHAP drops to an abysmal 0.38 [47]. Furthermore, these methods exhibit catastrophic instability under minor noise perturbation; for example, SHAP explanations in ophthalmology models demonstrated a 53% degradation in accuracy when exposed to just 10% noise [46].

These failures create the "explainability trap." When a clinician is presented with a visually convincing, biologically plausible, but mathematically false heat map, it induces severe automation bias. The clinician falsely believes they understand the model's reasoning, leading to unwarranted confidence in erroneous AI predictions [47].

Table 3. Mechanisms, Fidelity Scores, and Clinical Limitations of Explainable AI (XAI)

Methodologies

XAI Methodology	Core Mechanism	Fidelity Score (95% CI)	Primary Medical Application	Key Vulnerabilities and Clinical Limitations
LIME	Local surrogate modeling	0.81 (0.78 - 0.84)	EHR, Tabular Data	Computationally expensive; highly sensitive to noise injection [47].
Grad-CAM	Gradient-based activation mapping	0.54 (0.51 - 0.57)	Medical Imaging (CNNs)	Fails basic faithfulness checks; frequently generates plausible but false heat maps [47].
SHAP	Cooperative game theory (Shapley values)	0.38 (0.35 - 0.41)	EHR, Mixed Modalities	Severe degradation under image noise; low fidelity in complex diagnostic tasks [46].

A Comprehensive Framework for Accountability

To ensure patient safety, the field must transition from relying on deceptive post-hoc explainers toward a comprehensive, three-pillar framework for AI accountability [46].

- 1. Transparency:** Complete openness regarding the model's development, including the origin of the training data, preprocessing protocols, hyperparameter selections, and the explicit disclosure of known failure modes and demographic biases.
- 2. Interpretability:** Prioritizing the design of inherently interpretable model architectures (e.g.,

decision trees, generalized additive models) where the logical pathway from input to output is mathematically transparent from inception, rather than relying on black-box deep learning for every task.

3. **Explainability:** Reserving post-hoc techniques (like Grad-CAM) strictly as supplementary tools, deployed with explicit uncertainty quantification, and never serving as a substitute for true interpretability in high-stakes clinical scenarios.

Regulatory Governance and the SFDA Paradigm

The rapid deployment of continuously learning AI models challenges traditional medical device regulatory frameworks, which were originally designed for static hardware and locked software that produce the same result every time they are used [48]. A new global regulatory consensus is emerging, and the Kingdom of Saudi Arabia has established itself at the forefront of this legal evolution.

The Saudi Food and Drug Authority (SFDA) has promulgated comprehensive and legally binding requirements for AI and Big Data-based medical devices, specifically through its guidance document MDS-G010, designed to be read in conjunction with the broader Software as a Medical Device (SaMD) framework [49]. The SFDA evaluates AI tools intended for perioperative clinical decision-making, diagnosis, or patient management strictly based on their intended use, target users, and level of autonomy [50].

The SFDA's risk classification (MDS-G008) stratifies SaMD into four distinct tiers, aligning closely with the US FDA and the International Medical Device Regulators Forum (IMDRF) [51]:

- **Class A (Low Risk):** Software posing minimal potential harm, such as general wellness applications or basic administrative image viewers.
- **Class B (Low-Moderate Risk):** Diagnostic tools presenting higher risk but lacking life-

sustaining functions.

- **Class C (Moderate-High Risk):** Life-supporting software, advanced clinical decision support systems, and autonomous triage tools where an error poses a significant risk of severe injury or illness.
- **Class D (High Risk):** Software controlling life-sustaining interventions or closed-loop medication delivery systems.

To obtain market authorization under the SFDA guidelines, manufacturers must submit exhaustive evidence demonstrating algorithmic accuracy in analyzing Big Data to diagnose or predict disease. The SFDA mandates rigorous equivalence comparisons for machine-learning models; if a new AI product proves exact equivalence to an already approved device regarding intended use, ML model characteristics, and training data profiles, the SFDA may waive the requirement for novel clinical trials [52].

Crucially, the SFDA framework directly addresses the complexities of cybersecurity and continuous algorithmic learning. Devices utilizing cloud computing to transmit or store medical data are heavily scrutinized regarding server access control, user authentication, encryption, and de-identification protocols, with specific provisions outlining rules for private, public, and hybrid cloud infrastructures [52]. To manage algorithms that learn and adapt over time, regulators emphasize the use of Predetermined Change Control Plans (PCCPs) [48]. A PCCP allows manufacturers to prospectively outline how an AI algorithm will be retrained or modified using new clinical data in the post-market phase. As long as future modifications remain within the predefined boundaries of the approved PCCP, the manufacturer can update the AI model without submitting a completely new, time-consuming premarket application [48]. This innovative regulatory mechanism balances the need for continuous technological improvement with the absolute imperative of sustained patient safety.




Figure 3: SFDA SaMD Risk Stratification.

Conclusion

The integration of Artificial Intelligence across radiology, laboratory medicine, optometry, dentistry, and nursing represents the most profound technological shift in the modern history of healthcare. In domains heavily reliant on image analysis, such as optometry and radiology, AI has matured rapidly, transitioning from basic decision support to autonomous diagnostic screening. In dentistry and laboratory medicine, AI serves as an immensely powerful adjunctive tool, refining diagnostic specificity, preventing overtreatment, and utilizing synthetic data generation to overcome historical constraints related to patient privacy. In nursing, AI offers a dual-edged reality: it possesses the capability to eradicate overwhelming administrative burdens and optimize workflow, yet it simultaneously threatens to deskill the workforce and erode the empathetic core of the nurse-patient relationship if deployed without ethical constraint.

However, the realization of AI's transformative potential is heavily checked by critical systemic vulnerabilities. The recurrent failure of AI models to generalize across external populations, the dangerous clinical phenomenon of alert fatigue induced by flawed predictive analytics, and the

epistemological deceptiveness of post-hoc Explainable AI demonstrate unequivocally that mathematical accuracy in a laboratory setting does not automatically equate to clinical safety at the bedside. Furthermore, workforce readiness trails dangerously behind technological deployment. Medical, nursing, and technological education curricula—including those governed by the SCFHS in Saudi Arabia—must urgently undergo a radical redesign to integrate comprehensive AI literacy, digital data ethics, and the cultivation of epistemic trust into foundational training.

To navigate this complex landscape safely, healthcare systems, practitioners, and regulators must collectively abandon the perception of AI as an infallible computational oracle. Instead, AI must be conceptualized as a highly sophisticated, yet inherently flawed, medical device that requires relentless post-market surveillance, rigorous external validation across heterogeneous populations, and the stringent, adaptive regulatory oversight pioneered by agencies such as the SFDA. By harmonizing relentless technological innovation with uncompromising clinical governance, the medical community can harness the power of artificial intelligence to deliver patient care that is not only exponentially

more efficient but fundamentally safer, more accurate, and equitable.

References

- Tricco, A.C., E. Lillie, W. Zarin, K.K. O'Brien, H. Colquhoun, D. Levac, D. Moher, M.D.J. Peters, T. Horsley, L. Weeks, S. Hempel, E.A. Akl, C. Chang, J. McGowan, L. Stewart, L. Hartling, A. Aldcroft, M.G. Wilson, C. Garritty, S. Lewin, C.M. Godfrey, M.T. Macdonald, E.V. Langlois, K. Soares-Weiser, J. Moriarty, T. Clifford, Ö. Tunçalp, and S.E. Straus, PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med*, 2018. 169(7): p. 467-473.
- Vasudevan, R., G. Kandasamy, K. Venkatesan, P. Devanandan, S.M. Al Malh, and L.F. Alasmari, Patient Trust in AI-generated Medication Information and the Role of Clinical Pharmacists in Preventing Medication-related Safety Risks: A Cross-sectional Survey. *Journal of Patient Safety*, 2023: p. 10.1097.
- Ventura-Silva, J., M.M. Martins, L.d.L. Trindade, A.d.C.A. Faria, S. Pereira, S.S. Zuge, and O.M.P.L. Ribeiro, Artificial intelligence in the organization of nursing care: A scoping review. *Nursing Reports*, 2024. 14(4): p. 2733-2745.
- Alabduljabbar, A., S.U. Khan, A. Alsuhaibani, F. Almarshad, and Y.N. Altherwy, Medical imaging datasets, preparation, and availability for artificial intelligence in medical imaging. *Journal of Alzheimer's Disease Reports*, 2024. 8(1): p. 1471-1483.
- Nagendran, M., Y. Chen, C.A. Lovejoy, A.C. Gordon, M. Komorowski, H. Harvey, E.J. Topol, J.P. Ioannidis, G.S. Collins, and M. Maruthappu, Artificial intelligence versus clinicians: systematic review of design, reporting standards, and claims of deep learning studies. *bmj*, 2020. 368.
- Najjar, R., Redefining radiology: a review of artificial intelligence integration in medical imaging. *Diagnostics*, 2023. 13(17): p. 2760.
- Kelly, B.S., C. Judge, S.M. Bollard, S.M. Clifford, G.M. Healy, A. Aziz, P. Mathur, S. Islam, K.W. Yeom, A. Lawlor, and R.P. Killeen, *Radiology artificial intelligence: a systematic review and evaluation of methods (RAISE)*. *Eur Radiol*, 2022. 32(11): p. 7998-8007.
- Bao, C., F. Deng, and S. Zhao, *Machine-learning models for prediction of sepsis patients mortality*. *Medicina Intensiva (English Edition)*, 2023. 47(6): p. 315-325.
- Wong, A., E. Otles, J.P. Donnelly, A. Krumm, J. McCullough, O. DeTroyer-Cooley, J. Pestruie, M. Phillips, J. Konye, C. Penozza, M. Ghous, and K. Singh, *External Validation of a Widely Implemented Proprietary Sepsis Prediction Model in Hospitalized Patients*. *JAMA Intern Med*, 2021. 181(8): p. 1065-1070.
- Schinkel, M., T. van der Poll, and W.J. Wiersinga, *Artificial Intelligence for Early Sepsis Detection: A Word of Caution*. *Am J Respir Crit Care Med*, 2023. 207(7): p. 853-854.
- Habib, A., A. Lin, and R. Grant, *The Epic Sepsis Model Falls Short—The Importance of External Validation*. *JAMA Internal Medicine*, 2021. 181: p. 1040-1041.
- Byrne, M.F., N. Parsa, A.T. Greenhill, D. Chahal, O. Ahmad, and U. Bagci, *AI in clinical medicine: A practical guide for healthcare professionals*. 2023: John Wiley & Sons.
- Zhang, G., F. Shao, W. Yuan, J. Wu, X. Qi, J. Gao, R. Shao, Z. Tang, and T. Wang, *Predicting sepsis in-hospital mortality with machine learning: a multi-center study using clinical and inflammatory biomarkers*. *Eur J Med Res*, 2024. 29(1): p. 156.
- Muşat, F., D.N. Păduraru, A. Bolocan, C.A. Pălcău, A.M. Copăceanu, D. Ion, V. Jinga, and O. Andronic, *Machine Learning Models in Sepsis Outcome Prediction for ICU Patients: Integrating Routine Laboratory Tests-A Systematic Review*. *Biomedicines*, 2024. 12(12).
- Gao, J., Y. Lu, N. Ashrafi, I. Domingo, K. Alaei, and M. Pishgar, *Prediction of sepsis mortality in ICU patients using machine learning methods*. *BMC Medical Informatics and Decision Making*, 2024. 24(1): p. 228.
- Mao, B., L. Ling, Y. Pan, R. Zhang, W. Zheng, Y. Shen, W. Lu, Y. Lu, S. Xu, and J. Wu, *Machine learning for the prediction of in-hospital mortality in patients with spontaneous intracerebral hemorrhage in intensive care unit*. *Scientific reports*, 2024. 14(1): p. 14195.
- Yao, J., J. Lim, G.Y.S. Lim, J.C.L. Ong, Y. Ke, T.F. Tan, T.-E. Tan, S. Vujosevic, and D.S.W. Ting, *Novel artificial intelligence algorithms for diabetic retinopathy and diabetic macular edema*. *Eye and Vision*, 2024. 11(1): p. 23.
- Ferro Desideri, L., C. Rutigliani, P. Corazza, A. Nastasi, M. Roda, M. Nicolo, C.E. Traverso, and A. Vagge, *The upcoming role of Artificial Intelligence (AI) for retinal and glaucomatous diseases*. *J Optom*, 2022. 15 Suppl 1(Suppl 1): p. S50-s57.
- Ahmed, H.S. and C.J. Thrishulamurthy, *Advancing Diabetic Retinopathy Diagnosis: Leveraging Optical Coherence*

- Tomography Imaging with Convolutional Neural Networks*. Rom J Ophthalmol, 2023. **67**(4): p. 398-402.
- Yao, J., J. Lim, G.Y.S. Lim, J.C.L. Ong, Y. Ke, T.F. Tan, T.E. Tan, S. Vujosevic, and D.S.W. Ting, *Novel artificial intelligence algorithms for diabetic retinopathy and diabetic macular edema*. Eye Vis (Lond), 2024. **11**(1): p. 23.
- Miranda, M., J. Santos-Oliveira, A.M. Mendonça, V. Sousa, T. Melo, and Â. Carneiro, *Human versus artificial intelligence: validation of a deep learning model for retinal layer and fluid segmentation in optical coherence tomography images from patients with age-related macular degeneration*. Diagnostics, 2024. **14**(10): p. 975.
- Wolf, R.M., R. Channa, H.P. Lehmann, M.D. Abramoff, and T.Y.A. Liu, *Clinical Implementation of Autonomous Artificial Intelligence Systems for Diabetic Eye Exams: Considerations for Success*. Clin Diabetes, 2024. **42**(1): p. 142-149.
- Pitchika, V., M. Büttner, and F. Schwendicke, *Artificial intelligence and personalized diagnostics in periodontology: A narrative review*. Periodontology 2000, 2024. **95**(1): p. 220-231.
- Rahim, A., R. Khatoon, T.A. Khan, K. Syed, I. Khan, T. Khalid, and B. Khalid, *Artificial intelligence-powered dentistry: Probing the potential, challenges, and ethicality of artificial intelligence in dentistry*. Digit Health, 2024. **10**: p. 20552076241291345.
- Khanagar, S.B., A. Al-Ehaideb, P.C. Maganur, S. Vishwanathaiah, S. Patil, H.A. Baeshen, S.C. Sarode, and S. Bhandi, *Developments, application, and performance of artificial intelligence in dentistry—A systematic review*. Journal of dental sciences, 2021. **16**(1): p. 508-522.
- Fatima, A., I. Shafi, H. Afzal, I.D.L.T. Díez, D.R.-S.M. Lourdes, J. Breñosa, J.C.M. Espinosa, and I. Ashraf. *Advancements in dentistry with artificial intelligence: current clinical applications and future perspectives*. in *Healthcare*. 2022. MDPI.
- Hanna, M.G. and O. Ardon, *Digital pathology systems enabling quality patient care*. Genes Chromosomes Cancer, 2023. **62**(11): p. 685-697.
- Secinaro, S., D. Calandra, A. Secinaro, V. Muthurangu, and P. Biancone, *The role of artificial intelligence in healthcare: a structured literature review*. BMC medical informatics and decision making, 2021. **21**(1): p. 125.
- Baxi, V., R. Edwards, M. Montalto, and S. Saha, *Digital pathology and artificial intelligence in translational medicine and clinical practice*. Modern Pathology, 2022. **35**(1): p. 23-32.
- Seliem, M.A., A.M. Mohamadin, M.I.K. El-Sayed, Y. Ismail, and A.A. El-Husseiny, *The clinical signature of genetic variants and serum levels of macrophage migration inhibitory factor in Egyptian breast cancer patients*. Breast Cancer Research and Treatment, 2024. **208**(1): p. 57-66.
- Spies, N.C., C.W. Farnsworth, S. Wheeler, and C.R. McCudden, *Validating, implementing, and monitoring machine learning solutions in the clinical laboratory safely and effectively*. Clinical chemistry, 2024. **70**(11): p. 1334-1343.
- D'amico, S., D. Dall'Olio, C. Sala, L. Dall'Olio, E. Sauta, M. Zampini, G. Asti, L. Lanino, G. Maggioni, and A. Campagna, *Synthetic data generation by artificial intelligence to accelerate research and precision medicine in hematology*. JCO Clinical Cancer Informatics, 2023. **7**: p. e2300021.
- Sun, C., J. van Soest, and M. Dumontier, *Generating synthetic personal health data using conditional generative adversarial networks combining with differential privacy*. J Biomed Inform, 2023. **143**: p. 104404.
- Shamszare, H. and A. Choudhury, *Clinicians' Perceptions of Artificial Intelligence: Focus on Workload, Risk, Trust, Clinical Decision Making, and Clinical Integration*. Healthcare (Basel), 2023. **11**(16).
- Ramadan, O.M.E., M.M. Alruwaili, A.N. Alruwaili, M.G. Elsehrawy, and S. Alanazi, *Facilitators and barriers to AI adoption in nursing practice: a qualitative study of registered nurses' perspectives*. BMC nursing, 2024. **23**(1): p. 891.
- .Yelne, S., M. Chaudhary, K. Dod, A. Sayyad, and R. Sharma, *Harnessing the power of AI: a comprehensive review of its impact and challenges in nursing science and healthcare*. Cureus, 2023. **15**(11).
- Dailah, H.G., M. Koriri, A. Sabei, T. Kriry, and M. Zakri, *Artificial Intelligence in Nursing: Technological Benefits to Nurse's Mental Health and Patient Care Quality*. Healthcare (Basel), 2024. **12**(24).
- Choudhury, A. and Z. Chaudhry, *Large language models and user trust: consequence of self-referential learning loop and the deskilling of health care professionals*. Journal of Medical Internet Research, 2024. **26**: p. e56764.

- Alanezi, F., *Factors influencing patients' engagement with ChatGPT for accessing health-related information*. Critical Public Health, 2024. **34**(1): p. 1-20.
- Issa, W.B., A. Shorbagi, A. Al-Sharman, M. Rababa, K. Al-Majeed, H. Radwan, F. Refaat Ahmed, N. Al-Yateem, R. Mottershead, and D.N. Abdelrahim, *Shaping the future: perspectives on the integration of artificial intelligence in health profession education: a multi-country survey*. BMC Medical Education, 2024. **24**(1): p. 1166.
- Alruwaili, M.M., F.H. Abuadas, M. Alsadi, A.N. Alruwaili, O.M. Elsayed Ramadan, M. Shaban, A. Al Thobaity, S.M. Alkahtani, and R.A. El Arab, *Exploring nurses' awareness and attitudes toward artificial intelligence: implications for nursing practice*. Digital health, 2024. **10**: p. 20552076241271803.
- Derakhshanian, S., L. Wood, and E. Arruzza, *Perceptions and attitudes of health science students relating to artificial intelligence (AI): A scoping review*. Health Science Reports, 2024. **7**(8): p. e2289.
- Ali, H., M.A. Muzammil, D.S. Dahiya, F. Ali, S. Yasin, W. Hanif, M.K. Gangwani, M. Aziz, M. Khalaf, and D. Basuli, *Artificial intelligence in gastrointestinal endoscopy: a comprehensive review*. Annals of gastroenterology, 2024. **37**(2): p. 133.
- Zhang, H. and K. Ogasawara, *Grad-CAM-Based Explainable Artificial Intelligence Related to Medical Text Processing*. Bioengineering (Basel), 2023. **10**(9).
- Van der Velden, B.H., H.J. Kuijf, K.G. Gilhuijs, and M.A. Viergever, *Explainable artificial intelligence (XAI) in deep learning-based medical image analysis*. Medical image analysis, 2022. **79**: p. 102470.
- Muhammad, D. and M. Bendeache, *Unveiling the black box: A systematic review of Explainable Artificial Intelligence in medical image analysis*. 2024.
- Alhazmi, A., *Explainable AI in Medical Imaging and Diagnosis: A Critical Review of Methods, Clinical Translation Barriers, and an Integrated Evaluation Framework*. AI in Clinical Medicine, 2026. **2**.
- Fraser, A.G., E. Biasin, B. Bijnens, N. Bruining, E.G. Caiani, K. Cobbaert, R.H. Davies, S.H. Gilbert, L. Hovestadt, and E. Kamenjasevic, *Artificial intelligence in medical device software and high-risk medical devices—a review of definitions, expert recommendations and regulatory initiatives*. Expert review of medical devices, 2023. **20**(6): p. 467-491.
- Solaiman, B., *Regulating AI-Based Medical Devices in Saudi Arabia: New Legal Paradigms in an Evolving Global Legal Order*. Asian Bioeth Rev, 2024. **16**(3): p. 373-389.
- Solaiman, B., *Regulating AI-Based Medical Devices in Saudi Arabia: New Legal Paradigms in an Evolving Global Legal Order*. Asian Bioethics Review, 2024. **16**: p. 373-389.
- Bhaskar, R., M. Ola, S.S. Saharan, and V. Nikam, *Regulatory requirements for Medical Device Registration in Kingdom of Saudi Arabia, US and European Union*. International Journal Of Drug Regulatory Affairs, 2023. **11**(2): p. 75-85.
- Solaiman, B., A. Bashir, and F. Dieng, *Regulating AI in health in the Middle East: case studies from Qatar, Saudi Arabia and the United Arab Emirates*. Research handbook on health, AI and the law, 2024: p. 332-354.